Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
The main purpose of the project is to evaluate the disease free survival and overall survival
in patients diagnosed with acute lymphoblastic leukemia undergoing allogeneic hematopoietic
stem cell transplantation (allo-HSCT) adding gemcitabine to the standard institutional
conditioning regimen based on two alkylating drugs, reduced busulfan and cyclophosphamide
(reduced BUCY 2).
Phase:
Phase 2
Details
Lead Sponsor:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran